201 related articles for article (PubMed ID: 29433055)
1. Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience.
Lv L; Hu Y; Zhou P; Zhang S; Yin S; Zhang N; Jiang S
Clin Neurol Neurosurg; 2018 Apr; 167():24-30. PubMed ID: 29433055
[TBL] [Abstract][Full Text] [Related]
2. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
[TBL] [Abstract][Full Text] [Related]
3. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Effects of Intracapsular Debulking and Adjuvant Somatostatin Analogs for Growth Hormone-Secreting Pituitary Macroadenoma: 10 Years of Experience in a Single Institute.
Shen SC; Shen CC; Pu TW; Cheng WY
World Neurosurg; 2019 Jun; 126():e41-e47. PubMed ID: 30716503
[TBL] [Abstract][Full Text] [Related]
5. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
Shimon I; Jallad RS; Fleseriu M; Yedinak CG; Greenman Y; Bronstein MD
Eur J Endocrinol; 2015 Jun; 172(6):707-13. PubMed ID: 25792375
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and therapeutic outcomes of acromegalic patients with giant growth hormone-secreting pituitary adenomas: a single-center study of 67 cases.
Chen M; Duan L; Miao H; Yu N; Yang S; Wang L; Gong F; Yao Y; Zhu H
Pituitary; 2023 Dec; 26(6):675-685. PubMed ID: 37847430
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.
Hofstetter CP; Mannaa RH; Mubita L; Anand VK; Kennedy JW; Dehdashti AR; Schwartz TH
Neurosurg Focus; 2010 Oct; 29(4):E6. PubMed ID: 20887131
[TBL] [Abstract][Full Text] [Related]
9. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
10. Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.
Duan L; Zhu H; Xing B; Gu F
BMC Endocr Disord; 2017 Sep; 17(1):55. PubMed ID: 28874187
[TBL] [Abstract][Full Text] [Related]
11. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
13. Endoscopic therapy and curative effect in pituitary adenoma patients complicated by acromegalic cardiomyopathy.
Zhou H; Zha Z; Li X; Chen X; Wang J; Su Z
Neurosurg Rev; 2018 Jul; 41(3):869-875. PubMed ID: 29238923
[TBL] [Abstract][Full Text] [Related]
14. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.
Zhang L; Wu X; Yan Y; Qian J; Lu Y; Luo C
Brain Dev; 2015 Feb; 37(2):181-90. PubMed ID: 24815226
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
16. Final Outcome in Growth Hormone-Secreting Adenomas After Combination of Maximal Tumor Resection and Medical Treatment.
Torres A; Sanmillan JL; Lau R; Gabarros A
World Neurosurg; 2021 Oct; 154():e292-e301. PubMed ID: 34252630
[TBL] [Abstract][Full Text] [Related]
17. The multimodal management of GH-secreting pituitary adenomas: predictive factors, strategies and outcomes.
Buliman A; Tataranu LG; Ciubotaru V; Cazac TL; Dumitrache C
J Med Life; 2016; 9(2):187-92. PubMed ID: 27453753
[TBL] [Abstract][Full Text] [Related]
18. Giant growth hormone-secreting pituitary adenomas from the endocrinologist's perspective.
Koylu B; Firlatan B; Sendur SN; Oguz SH; Dagdelen S; Erbas T
Endocrine; 2023 Mar; 79(3):545-553. PubMed ID: 36318446
[TBL] [Abstract][Full Text] [Related]
19. The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas.
Selek A; Cetinarslan B; Canturk Z; Tarkun I; Hanazay Y; Vural C; Anik I; Ceylan S
Growth Horm IGF Res; 2019 Apr; 45():1-5. PubMed ID: 30731342
[TBL] [Abstract][Full Text] [Related]
20. Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry.
Mercado M; Abreu C; Vergara-López A; González-Virla B; Espinosa-de-Los-Monteros AL; Sosa-Eroza E; Cadena-Obando D; Cuevas-Ramos D; Portocarrero-Ortiz LA; Pérez-Reyes SP; Mercado-Cherem A; Ibarra-Salce R; Talavera JO
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32944780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]